Table 5.
Subset analysis for patients 50-60 years, characteristics and outcomes
| Variable | TBI, N(%) | BU, N (%) |
|---|---|---|
| Number of patients | 136 | 73 |
| Male | 73 (54) | 37 (51) |
| KPS >=90% | 81 (60) | 48 (66) |
| Disease stage at HCT | ||
| CR1 | 118 (87) | 64 (88) |
| CR2 | 18 (13) | 9 (12) |
| Cytogenetics | ||
| Poor, Ph+ | 67 (49) | 41 (56) |
| Poor, Ph− | 22 (16) | 11 (15) |
| Other | 40 (29) | 17 (23) |
| Med.wks achieve CR1(range) | 6 (1-47) | 11 (3-45) |
| Time from CR1 to HCT | ||
| ≤6 months | 103 (76) | 51 (69) |
| >6 months | 12 (9) | 9 (12) |
| PK for Bu dosing | 0 | 55 (75) |
| Donor type | ||
| SIB | 65 (48) | 44 (60) |
| MUD | 71 (52) | 29 (40) |
| Graft type | ||
| Bone marrow | 28 (21) | 8 (11) |
| Peripheral blood | 108 (79) | 65 (89) |
| Med. Mo. fu survivors (range) | 60 (3-120) | 38 (6-96) |
| Outcomes, 3-year | Prob (95%CI) | Prob(95%CI) | p-value |
|---|---|---|---|
| Relapse | 26 (19-34)% | 30 (19-42)% | 0.6 |
| TRM | 34 (26-43)% | 29 (20-41)% | 0.84 |
| DFS | 40 (31-49)% | 41 (29-53)% | 0.81 |
| OS | 40 (32-49)% | 49 (37-61)% | 0.55 |
Abbreviations: TBI, total body irradiation; BU, busulfan; N, number; KPS, Karnosfky performance status; CR, complete remission; HCT, hematopoietic cell transplantation; PK, pharmacokinetics; SIB, sibling; MUD, matched unrelated donor; Med, median; M, month; fu, follow up; TRM, treatment related mortality; DFS, disease-free survival; OS, overall survival; Prob, probability; CI, confidence interval